Skip to main content
Anteris Technologies Global Corp. logo

Anteris Technologies Global Corp. — Investor Relations & Filings

Ticker · AVR ISIN · US03675P1021 ASX Manufacturing
Open in API
Filings indexed 1,664 across all filing types
Latest filing 2025-05-13 Interim / Quarterly Rep…
Country US United States of America
Listing ASX AVR

About Anteris Technologies Global Corp.

https://anteristech.com/

Anteris Technologies is a structural heart company focused on the development and commercialization of medical devices for heart valve disease. Its lead product is the DurAVR® Transcatheter Heart Valve (THV), a biomimetic valve designed for patients with severe aortic stenosis. The DurAVR® THV is engineered to mimic the performance of a healthy human aortic valve, aiming to restore normal, laminar blood flow. Clinical studies have shown the device delivers a favorable hemodynamic profile, characterized by low pressure gradients and a significant reduction in prosthesis-patient mismatch (PPM), even in patients with challenging anatomies. The company is advancing its technology through pivotal clinical trials to establish a new standard in transcatheter aortic valve replacement (TAVR) and improve long-term patient outcomes.

Recent filings

Filing Released Lang Actions
Quarterly Results Announcement and SEC Form 10-Q 36 pages 615.7KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'ASX Quarterly Results Announcement' and prominently references a Form 10-Q Quarterly Report for the quarter ended March 31, 2025. It includes detailed financial statements, management discussion and analysis, risk factors, and other comprehensive financial information typical of a quarterly report. The document is about 15,000 characters long, indicating it is a full report rather than a brief announcement or certification. The presence of condensed consolidated financial statements and detailed analysis confirms it is a substantive quarterly financial report. Therefore, the document fits the definition of an Interim / Quarterly Report (IR).
2025-05-13 English
Results for the First Quarter of 2025 5 pages 293.6KB
Interim / Quarterly Report Classification · 100% confidence The document is a detailed quarterly financial and operational update from Anteris Technologies Global Corp. It includes financial results for the quarter ended March 31, 2025, clinical trial updates, business operations, and corporate activities. The text references a Form 10-Q filing for detailed financial information, indicating this is a quarterly report. The document contains substantive financial data such as net sales, loss after income tax, R&D expenses, and SG&A expenses, as well as operational and clinical trial progress. It is not merely an announcement of a report or a certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2025-05-13 English
Statement of CDIs on issue - AVR 5 pages 19.1KB
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Appendix 4A - Statement of CDIs on issue' and contains detailed monthly data on the number and class of CHESS Depositary Interests (CDIs) and other securities issued by Anteris Technologies Global Corp. It includes specific ASX security codes, descriptions, and net differences in securities issued between months. The document is dated May 7, 2025, and reports data for April 2025. This type of document is a regulatory announcement related to changes in capital structure, specifically the issuance and transfer of securities and CDIs. It is not a full financial report, earnings release, or management discussion. It is a formal announcement of securities on issue, which fits the category of Share Issue/Capital Change (SHA). The document length (7855 characters) and content confirm it is a detailed statement rather than a brief announcement or a report publication notice.
2025-05-06 English
10-K/A
Annual Report FY 2024
2025-04-29 English
SEC Form 10-K/A 34 pages 501.7KB
Annual Report Classification · 100% confidence The document is titled 'Form 10-K/A' which indicates it is an amendment to an Annual Report on Form 10-K. It references the fiscal year ended December 31, 2024, and mentions filing with the SEC. The text includes detailed corporate governance information, board of directors, executive officers, and other disclosures typical of an Annual Report. It explicitly states it is an amendment to the Annual Report on Form 10-K. The document length is substantial (15,000 characters), and it contains detailed report content, not just an announcement or certification. Therefore, this document is an amended Annual Report (10-K/A), which falls under the Annual Report category (10-K).
2025-04-29 English
Notification of cessation of securities - AVR 5 pages 17.1KB
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Appendix 3H - Notification of cessation of securities' and contains detailed information about securities that have ceased, including option expiries and lapses of conditional rights. It provides specifics such as security codes, reasons for cessation, dates, and updated issued capital figures. The document is a formal announcement to the ASX about changes in the company's issued securities, specifically the cessation of certain securities. This type of document corresponds to a regulatory announcement about changes in capital structure, but it is not a full financial report or earnings release. It is not a report publication announcement since it contains substantive details about the cessation event itself. The best fitting category is 'Share Issue/Capital Change' (SHA), which covers announcements regarding new share issues, stock splits, or other capital changes, including cessation of securities.
2025-04-28 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.